Super Research Guy
Transcend Event Driven Research
Aug. 1, 2014, 9:14 AM
Jan. 10, 2014, 2:05 PM
- Shares of PharMerica (PMC +23.9%) are on their way to logging a banner session.
- The company has completed the acquisition of BGS Pharmacy Partners, a deal which should be accretive this year.
- BGS provides services to customers in Nevada and Utah.
- Financial terms weren't disclosed. (PR)
Feb. 21, 2012, 9:58 AM
Omnicare (OCR -0.5%) withdraws its hostile offer for nursing-home pharmacy company PharMerica (PMC -2.6%) a month after federal regulators raised antitrust issues. PMC says it is "pleased" with the decision, believing that the offer undervalued the company; OCR says it will provide an update to strategies on Thursday, when it reports its Q4 results.| Feb. 21, 2012, 9:58 AM
Jan. 30, 2012, 10:01 AMThough PharMerica (PMC -12.6%) remains off sharply following the FTC's decision to block Omnicare's (OCR -1.4%) hostile bid, the company says it's pleased with the move. Meanwhile, Barclays and Cowen recommend buying Omnicare on any post-FTC weakness, arguing its fundamentals are sound regardless of whether a merger occurs. | Jan. 30, 2012, 10:01 AM
Jan. 27, 2012, 5:26 PM
Jan. 12, 2012, 7:54 AM
The FTC is reportedly set to block Omnicare's (OCR) proposed $716M offer for fellow pharmacy provider PharMerica (PMC), with a decision expected by the end of next week. "The FTC is not offering Omnicare any remedies," a source says, so it is not trying to look for ways to OK the transaction. PharMerica shares are -11.1%.| Jan. 12, 2012, 7:54 AM
Aug. 25, 2011, 3:27 PM
Aug. 25, 2011, 10:23 AM
Pharmerica (PMC +1.4%) sends a letter to Omnicare (OCR -2.2%) to "set the record straight" on the latter's $441M offer to purchase the company: It "undervalues the company and is not in the best interest of PharMerica or its stockholders." Antitrust clearance to combine the two top players in institutional pharmacy would be "difficult to achieve," the letter says.| Aug. 25, 2011, 10:23 AM
Aug. 23, 2011, 8:51 AM
Omnicare (OCR) offers to purchase all outstanding shares of smaller rival PharMerica (PMC) for $441M, or $15.00/share, representing a 37.2% premium from Monday's close. In a letter to PMC's board, Omnicare CEO John Figueroa says he prefers to reach a negotiated deal but will take the offer directly to shareholders if needed. PMC +37.1%, OCR +8.8% premarket.| Aug. 23, 2011, 8:51 AM